R. 1. Turner, N. Grose, and R. , Fibroblast growth factor signalling: from development to cancer, Nature Reviews Cancer, vol.351, issue.2, pp.116-129, 2010.
DOI : 10.1038/nrc2780

L. Hote, C. Knowles, and M. , Cell responses to FGFR3 signalling: growth, differentiation and apoptosis, Experimental Cell Research, vol.304, issue.2, pp.417-431, 2005.
DOI : 10.1016/j.yexcr.2004.11.012

J. Colvin, B. Bohne, G. Harding, D. Mcewen, and D. Ornitz, Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3, Nature Genetics, vol.25, issue.4, pp.390-397, 1996.
DOI : 10.1016/0092-8674(91)90034-V

C. Li, L. Chen, T. Iwata, M. Kitagawa, X. Fu et al., A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors, Human Molecular Genetics, vol.8, issue.1, pp.35-44, 1999.
DOI : 10.1093/hmg/8.1.35

S. Arnaud-dabernat, M. Kritzik, A. Kayali, Y. Zhang, G. Liu et al., FGFR3 Is a Negative Regulator of the Expansion of Pancreatic Epithelial Cells, Diabetes, vol.56, issue.1, pp.96-106, 2007.
DOI : 10.2337/db05-1073

S. Arnaud-dabernat, D. Yadav, and N. Sarvetnick, FGFR3 contributes to intestinal crypt cell growth arrest, Journal of Cellular Physiology, vol.200, issue.1, pp.261-268, 2008.
DOI : 10.1002/jcp.21401

D. Cappellen, D. Oliveira, C. Ricol, D. De-medina, S. Bourdin et al., Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas, Nat Genet, vol.23, pp.18-20, 1999.

S. Hernandez, E. Lopez-knowles, J. Lloreta, M. Kogevinas, A. Amoros et al., Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas, Journal of Clinical Oncology, vol.24, issue.22, pp.3664-3671, 2006.
DOI : 10.1200/JCO.2005.05.1771

S. Hernandez, A. Toll, E. Baselga, A. Ribe, J. Azua-romeo et al., Real FX: Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors, pp.1664-1666, 2007.

J. Jang, K. Shin, Y. Park, R. Lee, W. Mckeehan et al., Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer, Cancer Res, vol.60, pp.4049-4052, 2000.

G. Sonvilla, S. Allerstorfer, C. Heinzle, S. Stattner, J. Karner et al., Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration, British Journal of Cancer, vol.13, issue.7
DOI : 10.1677/erc.0.0080161

M. Chesi, E. Nardini, L. Brents, E. Schrock, T. Ried et al., Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3, Nature Genetics, vol.56, issue.3, pp.260-264, 1997.
DOI : 10.1074/jbc.270.51.30643

T. Kuilman, C. Michaloglou, W. Mooi, and D. Peeper, The essence of senescence, Genes & Development, vol.24, issue.22, pp.2463-2479, 2010.
DOI : 10.1101/gad.1971610

D. Ornitz, J. Xu, J. Colvin, D. Mcewen, C. Macarthur et al., Receptor specificity of the fibroblast growth factor family, J Biol Chem, vol.271, pp.15292-15297, 1996.

S. Efrat, D. Fusco-demane, H. Lemberg, O. Emran, and X. Wang, Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene., Proceedings of the National Academy of Sciences, vol.92, issue.8, pp.3576-3580
DOI : 10.1073/pnas.92.8.3576

T. Plath, M. Peters, K. Detjen, M. Welzel, Z. Von-marschall et al., Overexpression of pRB in Human Pancreatic Carcinoma Cells: Function in Chemotherapy-Induced Apoptosis, JNCI Journal of the National Cancer Institute, vol.94, issue.2, pp.129-142, 2002.
DOI : 10.1093/jnci/94.2.129

Z. Li, Y. Zhu, E. Plowright, P. Bergsagel, M. Chesi et al., The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells, Blood, vol.97, issue.8, pp.2413-2419, 2001.
DOI : 10.1182/blood.V97.8.2413

I. Bernard-pierrot, A. Brams, C. Dunois-larde, A. Caillault, S. De-medina et al., Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b, Carcinogenesis, vol.27, issue.4, pp.740-747, 2006.
DOI : 10.1093/carcin/bgi290

M. Hirotsu, T. Setoguchi, Y. Matsunoshita, H. Sasaki, H. Nagao et al., Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells, British Journal of Cancer, vol.61, issue.12, pp.2030-2037, 2009.
DOI : 10.1038/sj.bjc.6605142

T. Ishibe, T. Nakayama, T. Okamoto, T. Aoyama, K. Nishijo et al., Disruption of Fibroblast Growth Factor Signal Pathway Inhibits the Growth of Synovial Sarcomas: Potential Application of Signal Inhibitors to Molecular Target Therapy, Clinical Cancer Research, vol.11, issue.7, pp.2702-2712, 2005.
DOI : 10.1158/1078-0432.CCR-04-2057

K. Sibley, D. Cuthbert-heavens, and M. Knowles, Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma, Oncogene, vol.20, issue.6, pp.686-691, 2001.
DOI : 10.1038/sj.onc.1204110

H. Dai, R. Holm, G. Kristensen, V. Abeler, A. Borresen-dale et al., Fibroblast Growth Factor Receptor 3 (FGFR3)???Analyses of the S249C Mutation and Protein Expression in Primary Cervical Carcinomas, Analytical Cellular Pathology, vol.23, issue.2, pp.45-49, 2001.
DOI : 10.1155/2001/521873

P. Mhawech-fauceglia, R. Cheney, G. Fischer, A. Beck, and F. Herrmann, FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer, European Journal of Surgical Oncology (EJSO), vol.32, issue.2, pp.231-237, 2006.
DOI : 10.1016/j.ejso.2005.11.018

K. Zieger, N. Marcussen, M. Borre, T. Orntoft, and L. Dyrskjot, Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development

M. Knowles, Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target, World Journal of Urology, vol.11, issue.3, pp.581-593, 2007.
DOI : 10.1007/s00345-007-0213-4

L. Roger, L. Jullien, V. Gire, and P. Roux, Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells, Journal of Cell Science, vol.123, issue.8, pp.1295-1305, 2010.
DOI : 10.1242/jcs.061002
URL : https://hal.archives-ouvertes.fr/hal-00481004

Y. Hayashida, K. Honda, M. Idogawa, Y. Ino, M. Ono et al., E-Cadherin Regulates the Association between ??-Catenin and Actinin-4, Cancer Research, vol.65, issue.19, pp.8836-8845, 2005.
DOI : 10.1158/0008-5472.CAN-05-0718

L. Mcinroy and A. Maatta, Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion, Biochemical and Biophysical Research Communications, vol.360, issue.1, pp.109-114, 2007.
DOI : 10.1016/j.bbrc.2007.06.036

D. Ronchetti, A. Greco, S. Compasso, G. Colombo, P. Dell-'era et al., Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations, Oncogene, vol.20, issue.27, pp.3553-3562, 2001.
DOI : 10.1038/sj.onc.1204465

H. Leung, W. Gullick, and N. Lemoine, Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer, International Journal of Cancer, vol.64, issue.5, pp.667-675, 1994.
DOI : 10.1002/ijc.2910590515

P. Krejci, J. Prochazkova, J. Smutny, K. Chlebova, P. Lin et al., FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence, Bone, vol.47, issue.1, pp.102-110, 2010.
DOI : 10.1016/j.bone.2010.03.021

S. Hubackova, Z. Novakova, K. Krejcikova, M. Kosar, J. Dobrovolna et al., Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling, Cell Cycle, vol.9, issue.15, pp.3085-3099, 2010.
DOI : 10.4161/cc.9.15.12521

T. Bellido, O. Brien, C. Roberson, P. Manolagas, and S. , Transcriptional Activation of the p21WAF1,CIP1,SDI1 Gene by Interleukin-6 Type Cytokines: A PREREQUISITE FOR THEIR PRO-DIFFERENTIATING AND ANTI-APOPTOTIC EFFECTS ON HUMAN OSTEOBLASTIC CELLS, Journal of Biological Chemistry, vol.273, issue.33, pp.21137-21144, 1998.
DOI : 10.1074/jbc.273.33.21137

M. Lafitte, B. Rousseau, I. Moranvillier, M. Taillepierre, E. Peuchant et al., In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens, Molecular Cancer, vol.11, issue.1, p.81, 2012.
DOI : 10.1038/sj.mt.6300030
URL : https://hal.archives-ouvertes.fr/inserm-00776648